Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Draft Guidance Drills Down With Details To Cut Pediatric Acetaminophen Overdose Risk

This article was originally published in The Tan Sheet

Executive Summary

FDA suggests new and repeats previous recommendations to reduce the risk of pediatric overdose with acetaminophen products due either to unsupervised ingestion or therapeutic errors. The guidance includes greater detail on delivery devices and labeling information for pediatric acetaminophen OTCs.

You may also be interested in...



In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor

Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.

In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor

Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.

FDA Budget Request Reminds Congress: OTC Rulemakings Take Time

In its fiscal 2017 budget proposal, FDA responds to House and Senate appropriators' questions included in their reports on the agency's fiscal 2016 appropriation. Appropriators question why FDA has not approved additional OTC sunscreen active ingredients since Congress passed the Sunscreen Innovation Act in 2014.

Related Content

Topics

UsernamePublicRestriction

Register

PS107209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel